Since they are significantly overexpressed in patient-derived melanoma samples compared to normal skin samples and are also significantly co-expressed with TP-472 target epigenetic regulator BRD7, they can be targeted either alone or in combination with TP-472 and thus serve as a new option for melanoma therapy. Here, BRD7 is linked to melanoma.